Starling Oncology, Inc.

STLNW

Exchange: Nasdaq
Industry: Services-Offices & Clinics of Doctors of Medicine
SEC CIK: 0001799191

SEC filings (opens in a new tab)

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $163.5K in total; no superinvestor holds it.

Other share classesDFPH STLN

Q1 2023 vs. Q4 2022

How the institutions holding Starling Oncology, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023 All holders in Q4 2022

13F holders of STLNW: Q4 2022 compared with Q1 2023
Measure	Q4 2022	Q1 2023	Change
Holders	14	17	+3
Shares	4.05M	4.51M	+454.4K (+11.2%)
Value	$346.4K	$232.3K	−$114.1K (−32.9%)

New holders (4)

Institutions that held Starling Oncology, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to STLNW in Q1 2023
Institution	Shares	Value	% of portfolio
Davidson Kempner Partners	318,710	$19.3K	0.00%
Citadel Advisors LLC	17,307	$1.64K	0.00%
Clear Street LLC	193	$13	0.00%
Bank of America Corp	100	$6	0.00%

Sold out (1)

Institutions that held Starling Oncology, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of STLNW in Q1 2023
Institution	Shares, Q4 2022	Value, Q4 2022
UBS Group AG	610	$67